Home / Market News / $MRNA
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Jefferies Adjusts Price Target on Moderna to $215 From $150

Oct 22, 2026, 12:03 PM UTC · Primary ticker $MRNA

Jefferies has increased its price target for Moderna's stock from $150 to $215, indicating a more optimistic outlook on the biotechnology company's valuation and market position. This upgrade suggests a positive sentiment from a notable financial institution, which could influence investor perception and short-term trading activity for MRNA.

Jefferies has significantly raised its price target for Moderna (MRNA) from $150 to $215. This adjustment reflects a more bullish stance from the firm on Moderna's future prospects, likely driven by updated analysis of its pipeline, market share, or financial performance. For traders, this is a positive signal that could lead to increased buying interest in the short term, as institutional upgrades often influence retail and institutional investors. The long-term implications depend on whether Moderna can meet or exceed the expectations embedded in this new price target. A key opportunity for traders is to capitalize on potential upward momentum, while the risk lies in the possibility that the market has already priced in such upgrades or that future company performance may not justify the higher valuation.

$MRNA positive Price target increase by Jefferies
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.